D. Paul

A randomized, double-masked, placebo-controlled study of alicaforsen, an antisense inhibitor of intercellular adhesion molecule 1, for the treatment of subjects with active Crohn's disease.

W. Chey, R. Yu, E. Chuang, 2007, Clinical Gastroenterology and Hepatology.

P661 Early histological improvement demonstrated with oral ozanimod in patients with moderately to severely active Crohn’s disease in the STEPSTONE trial

G. D'Haens, B. Feagan, K. Usiskin, 2019, Journal of Crohn's and Colitis.

Two phase 3 studies of alicalorsen (ISIS-2302), an antisense oligonucleotide to human ICAM-1, in the treatment of moderate to severe Crohn's disease

M. Vos, R. Fogel, M. Safdi, 2005 .